AFIB News and Press, Acutus Medical Inc. From 10/31/22

Research Highlights: An analysis of more than 1.3 million Asian American adults, ages 18-44, hospitalized for atrial fibrillation, found an increase in the prevalence of five modifiable risk factors for cardiovascular disease (CVD), including obesity, Type 2 diabetes, hypertension, smoki...

CARLSBAD, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that it will release its third quarter 2022 financia...

Acutus Medical ( NASDAQ: AFIB ) filed an application to the U.S. Food & Drug Administration (FDA) seeking approval of its AcQBlate Force Sensing Ablation Catheter and System. The premarket approval application (PMA) was backed by data from a study called ...

SAN JOSE, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- BrightInsight, Inc., provider of the leading global platform for biopharma and medtech regulated digital health solutions, announced today the appointment of Tamara Elias, M.D., Senior Vice President at Nuance, and Scott Huennek...

( NewMediaWire ) - August 29, 2022 - DALLAS  — Atrial fibrillation (AFib) is an irregular and often very rapid heart rhythm (arrhythmia) affecting an estimated 2.5 to 5 million people in the U.S., and can lead to stroke, heart failure and premature death, according to the American...

Acutus Medical, Inc. (AFIB) Q2 2022 Earnings Conference Call August 11, 2022 04:30 PM ET Company Participants Caroline Corner - Investor Relations David Roman - Chief Executive Officer & Chief Financial Officer Conference Call Participants William Plo...

Image source: The Motley Fool. Acutus Medical, Inc. (NASDAQ: AFIB) Q2 2022 Earnings Call Aug 11, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Acutus Medical, Inc. (AFIB) Q2 2022 Earnings Call Transcript

Acutus Medical press release ( NASDAQ: AFIB ): Q2 Non-GAAP EPS of -$0.93 misses by $0.17 . Revenue of $4.1M (-13.0% Y/Y) beats by $0.13M . “Our teams continued to execute our strategy in the second quarter, as we intensify focus on utilization and proced...

CARLSBAD, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported results for the second...

CARLSBAD, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that it will release its second quarter 2022 financi...